Michael S. Cookson, MD, MMHC, presented “New Approaches to Metastatic Hormone Sensitive Prostate Cancer” during the 5th Annual Oklahoma Prostate & Urologic Cancers Symposium on September 13th, 2019 in Oklahoma City, Oklahoma.
How to cite: Cookson, Michael S. “New Approaches to Metastatic Hormone Sensitive Prostate Cancer” September 13th, 2019. Accessed Jul 2024. https://grandroundsinurology.com/new-approaches-to-metastatic-hormone-sensitive-prostate-cancer/
New Approaches to Metastatic Hormone Sensitive Prostate Cancer – Summary:
Michael S. Cookson, MD, MMHC, Professor of Urology at the University of Oklahoma, reviews the current treatment landscape of metastatic hormone-sensitive prostate cancer (mHSPC). He goes on to discuss several aspects of the disease, including classifying patients into low or high risk, how to incorporate androgen axis inhibitors with ADT in managing newly diagnosed patients, and how to identify patients who may be candidates for chemotherapy plus ADT in patients with mHSPC.
About The 5th Annual Prostate & Urologic Cancer Symposium:
The Prostate & Urologic Cancers Symposium is held through the University of Oklahoma and the Stephenson Cancer Center to provide new insights in the treatment of prostate and urologic cancers. This single-day program consists of lectures and case discussions highlighting a multidisciplinary approach to urologic cancer care and integration of new technology in the evaluation and treatment of patients with prostate and/or urologic cancers. Dr. Cookson presented this lecture during the 5th iteration of this summit in 2019.
Please visit our collection page to view additional educational activtities from this symposium.
ABOUT THE AUTHOR
Michael S. Cookson, MD, MMHC, is Professor and Chairman of the Department of Urology and holds the Donald D. Albers Endowed Chair in Urology at the University of Oklahoma Health Sciences Center in Oklahoma City. He has authored some 240 peer-reviewed journal publications as well as more than 30 chapters of various textbooks, and he is nationally recognized for his outstanding contributions to urologic oncology. Dr. Cookson completed his Urology Residency at the University of Texas, San Antonio, and completed his Urologic Oncology Fellowship at Memorial Sloan-Kettering Cancer Center in New York. From 1998 to 2013, he served as the Vice Chairman of Urologic Surgery and Director of the Urologic Oncology Fellowship Program at Vanderbilt University. Dr. Cookson has devoted much of his academic career to the management of patients with urologic cancers, with a strong emphasis on clinical guidelines, education, and evidenced-based medicine. He was a member of the AUA/ABU Examination Committee for 10 years, serving as Oncology Consultant and Pathology Editor. He also serves on the ABU Oral Examination Committee. He is a Co-Founder of the Oncology Knowledge Assessment Test (OKAT), an SUO-mandated examination. He also served as Chair for the OKAT for 5 years. In 2011, he received the President’s Distinguished Service Award from the SUO for educational contributions. He received the 2018 AUA Presidential Citation for Outstanding Service for his role in the development of the OKAT and as Chair of the Castration-Resistant Prostate Cancer Guidelines Committee at the AUA 2018 Annual Meeting. Dr. Cookson has previously served as a member of the AUA Guidelines on Localized Prostate Cancer Committee. Dr. Cookson is currently serving out the 2019-2020 term as the SUO President.